Failure of PDA closure within 1 week of administration of the first dose of indomethacin · symptomatic patent ductus arteriosus in preterm infants
Indomethacin leads to lower failure of PDA closure within 1 week of administration of the first… compared with placebo or control (high certainty).
1 finding from 1 review
Bronchopulmonary dysplasia at 28 days · symptomatic patent ductus arteriosus in preterm infants
Indomethacin showed no clear difference in bronchopulmonary dysplasia at 28 days compared with placebo or control (low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia · symptomatic patent ductus arteriosus in preterm infants
Indomethacin showed no clear difference in bronchopulmonary dysplasia at 36 weeks' gestation compared with placebo or control (low certainty).
1 finding from 1 review
All‐cause neonatal mortality before hospital discharge · symptomatic patent ductus arteriosus in preterm infants
Indomethacin showed no clear difference in all‐cause neonatal mortality before hospital discharge compared with placebo or control (moderate certainty).
1 finding from 1 review
Proportion of infants requiring surgical ligation of PDA · symptomatic patent ductus arteriosus in preterm infants
Indomethacin showed no clear difference in proportion of infants requiring surgical ligation of PDA compared with placebo or control (moderate certainty).
1 finding from 1 review
NEC ≥ stage II · symptomatic patent ductus arteriosus in preterm infants
Indomethacin showed no clear difference in NEC (≥ Bell stage 2) compared with placebo or control (low certainty).
1 finding from 1 review
Mucocutaneous or gastrointestinal bleeding · symptomatic patent ductus arteriosus in preterm infants
Indomethacin showed no clear difference in mucocutaneous or gastrointestinal bleeding compared with placebo or control (low certainty).
1 finding from 1 review